Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Acta Haematol

Retrieve available abstracts of 27 articles:
HTML format



Single Articles


    August 2022
  1. NACHMIAS B, Krichevsky S, Filon D, Even-Or E, et al
    Monitoring minimal residual disease in RUNX1-mutated acute myeloid leukemia.
    Acta Haematol. 2022 Aug 5. pii: 000526353. doi: 10.1159/000526353.
    PubMed     Abstract available


  2. HE X, Jiang Y, Yu X, He F, et al
    A gene signature comprising seven pyroptosis-related genes predicts prognosis in pediatric patients with acute myeloid leukemia.
    Acta Haematol. 2022 Aug 5. pii: 000526346. doi: 10.1159/000526346.
    PubMed     Abstract available


    July 2022
  3. DENGLER J, Tesch H, Jentsch-Ullrich K, Gerhardt A, et al
    Treatment-free remission in real-world chronic myeloid leukemia patients: Insights from German hematology practices.
    Acta Haematol. 2022 Jul 29. pii: 000525935. doi: 10.1159/000525935.
    PubMed     Abstract available


  4. BERGER T, Shacham Abulafia A, Shimony S, Pasvolsky O, et al
    Prevalence and Clinical Characteristics of Paraproteinemia Associated with Chronic Myeloid Leukemia.
    Acta Haematol. 2022 Jul 29. pii: 000526168. doi: 10.1159/000526168.
    PubMed     Abstract available


  5. EDAHIRO T, Fukushima N, Otani T, Nakamori M, et al
    Progressive multifocal leukoencephalopathy in relapsed Ph+ acute lymphoblastic leukemia after cord blood transplantation and blinatumomab treatment: A case report and literature review.
    Acta Haematol. 2022 Jul 27. pii: 000526132. doi: 10.1159/000526132.
    PubMed     Abstract available


  6. GOTO H, Ogawa C, Iida H, Horibe K, et al
    Safety and efficacy of blinatumomab in Japanese adult and pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: final results from an expansion cohort.
    Acta Haematol. 2022 Jul 5. pii: 000525835. doi: 10.1159/000525835.
    PubMed     Abstract available


    June 2022
  7. PETERLIN P, Garnier A, Le Bourgeois A, Jullien M, et al
    Dramatic recovery after etoposide phosphate infusion for hemophagocytic lymphohistiocytosis/macrophage activation syndrome following treatment with tisagenlecleucel in a young patient with relapsed acute lymphoblastic leukemia: a case report.
    Acta Haematol. 2022 Jun 20. pii: 000525576. doi: 10.1159/000525576.
    PubMed     Abstract available


    May 2022
  8. ARRIGO G, D'Ardia S, Audisio E, Cerrano M, et al
    Gilteritinib in isolated breast relapse of FLT3positive acute myeloid leukemia: a case report and review of literature.
    Acta Haematol. 2022 May 17. pii: 000524878. doi: 10.1159/000524878.
    PubMed     Abstract available


  9. TO AQ, Ciurea SO, Kongtim P
    Acquired Factor V Deficiency: A New Cause of Bleeding in Patients with Chronic Myeloid Leukemia and Extreme Leukocytosis?
    Acta Haematol. 2022 May 2. pii: 000524630. doi: 10.1159/000524630.
    PubMed     Abstract available


    March 2022
  10. WANG ZY, Gao WH, Zhao HJ, Yin CR, et al
    Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis.
    Acta Haematol. 2022 Mar 1:1-11. doi: 10.1159/000511144.
    PubMed     Abstract available


    January 2022
  11. KIMURA SI, Nakamura Y, Kawamura M, Takeshita J, et al
    Neutropenia in the First Cycle of Consolidation Chemotherapy with High-Dose Cytarabine Is Not Associated with the Incidence of Relapse in Adult Acute Myeloid Leukemia Patients in First Complete Remission.
    Acta Haematol. 2022 Jan 19. pii: 000522037. doi: 10.1159/000522037.
    PubMed     Abstract available


  12. BIANCHI S, Capria S, Trisolini SM, Crisanti E, et al
    Myeloid Sarcoma: Diagnostic and Treatment Tools from a Monocentric Retrospective Experience.
    Acta Haematol. 2022;145:84-88.
    PubMed     Abstract available


  13. LAFFERTY N, Salmon M, Cross NCP, Singer I, et al
    Chronic Eosinophilic Leukaemia Associated with JAK2 Exon 13 Insertion/Deletion Mutations.
    Acta Haematol. 2022;145:201-206.
    PubMed     Abstract available


  14. UYGUN V, Karasu G, Yalcin K, Ozturkmen S, et al
    Timing of Initiation of Calcineurin Inhibitors in Pediatric Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Effects on Survival, Relapse, and Cytokine Release Syndrome.
    Acta Haematol. 2022;145:362-370.
    PubMed     Abstract available


  15. DESIKAN SP, Ravandi F, Pemmaraju N, Konopleva M, et al
    A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
    Acta Haematol. 2022;145:529-536.
    PubMed     Abstract available


  16. LIU X, Cui MM, Zhu HZ, Fu PY, et al
    MiR-199a-3p Overexpression Suppressed Cell Proliferation and Sensitized Chronic Myeloid Leukaemia Cells to Imatinib by Inhibiting mTOR Signalling.
    Acta Haematol. 2022;145:484-498.
    PubMed     Abstract available


    December 2021
  17. SHEN Y, Jia Y, Zhang R, Chen H, et al
    Using Circ-ANAPC7 as a Novel Type of Biomarker in the Monitoring of Acute Myeloid Leukemia.
    Acta Haematol. 2021 Dec 8:1-7. doi: 10.1159/000520446.
    PubMed     Abstract available


    November 2021
  18. PLOTKA A, Lewandowski K
    BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.
    Acta Haematol. 2021 Nov 24:1-9. doi: 10.1159/000519782.
    PubMed     Abstract available


    October 2021
  19. TAKAHASHI S
    Kinase Inhibitors and Interferons as Other Myeloid Differentiation Inducers in Leukemia Therapy.
    Acta Haematol. 2021 Oct 21:1-9. doi: 10.1159/000519769.
    PubMed     Abstract available


    September 2021
  20. CAI X, Wang J, Lu J, Jia Z, et al
    Adult Acute Myeloid Leukemia with the KMT2A-Mixed Lineage Leukemia T10 Fusion: An Analysis of 10 Cases Showed Common Features and Frequent Mutations in the RAS Signaling Pathway.
    Acta Haematol. 2021 Sep 22:1-7. doi: 10.1159/000518920.
    PubMed     Abstract available


  21. YANG S, Zhu R, Li N, Feng Y, et al
    Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
    Acta Haematol. 2021 Sep 20:1-9. doi: 10.1159/000518398.
    PubMed     Abstract available


  22. MIZRAHI N, Kugler E, Hayman L, Yeshurun M, et al
    T-Lymphoblastic Leukemia/Lymphoma and Thymoma: A Case Report and Review of the Literature of a Rare Association.
    Acta Haematol. 2021 Sep 17:1-5. doi: 10.1159/000519033.
    PubMed     Abstract available


    June 2021
  23. CRISTIANO G, Nanni J, Sartor C, Parisi S, et al
    Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement.
    Acta Haematol. 2021 Jun 15:1-5. doi: 10.1159/000516003.
    PubMed     Abstract available


  24. DANYLESKO I, Canaani J, Shimoni A, Fein J, et al
    Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
    Acta Haematol. 2021 Jun 8:1-7. doi: 10.1159/000515902.
    PubMed     Abstract available


    April 2021
  25. ZHANG X, Liu H, Zheng C, Tang B, et al
    Outcomes of Adolescents and Young Adults Compared with Children with Acute Leukemia after Single-Unit Unrelated Cord Blood Transplantation Using Myeloablative Conditioning without Antithymocyte Globulin.
    Acta Haematol. 2021 Apr 13:1-11. doi: 10.1159/000507973.
    PubMed     Abstract available


    January 2021
  26. SHAHIN OA, Chifotides HT, Bose P, Masarova L, et al
    Accelerated Phase of Myeloproliferative Neoplasms.
    Acta Haematol. 2021;144:484-499.
    PubMed     Abstract available


  27. PARK HS, Son BR, Shin KS, Byeon S, et al
    The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.
    Acta Haematol. 2021;144:649-659.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: